Future trials in germ cell malignancy (GCM) of the testis

European Journal of Surgical Oncology

Volumn 23, Issue 2, 1997, Pages 117-122

  Oliver, R T D ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Clinical trials; Germ cell malignancy; Testis

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; GERM CELL TUMOR; HIGH RISK PATIENT; HUMAN; MALE; PRIORITY JOURNAL; SEMINOMA; TESTIS CANCER;

EID: 0030905939     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(97)80003-0     Document Type: Article

References (29)

1. Oliver RTD, Ong J, Blandy JP, Altman D. Testis conservation studies in germ cell cancer justified by improved primary chemotherapy response and reduced delay 1978-1994. Br J Urol 1996; 78: 119-24.
2. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer. Treatment of disseminated germ-cell tumours with Cisplatin, Bleomycin, and either Vinblastine or Etoposide. N Engl J Med 1987; 316: 1435-40.
3. Motzer RJ, Bajorin DF, Schwartz LH, Mutter HS, Bosl GJ. Phase II trial of paclitaxel shows antitumour activity in patients with previously treated germ cell tumours. J Clin Oncol 1994; 12: 2277-83.
4. Pera MF, Koverle B, Masters JRE. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Br J Cancer 1994; 71: 904-6.
5. Beyer J, Mandanas R, Linkwsch W, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638-45.
6. Mead GM. International consensus on prognostic factor classification of metastatic germ cell tumour. Proc Am Soc Clin Oncol 1995; 14: 235. abst 615.
7. Nichols CR, Loehrer PJ, Einhorn LH, et al. Phase III study of cisplatin, etoposide and bleomycin (PVP16B) or etoposide, ifosfamide and cisplatin (VIP) in advanced stage germ cell tumors: an intergroup trial. Proc Am Soc Clin Oncol 1995; 14: abst. 632.
8. Kaye SB, Mead GM, Fossa S, et al. An MRC/EORTC randomised trial in poor prognosis metastatic teratoma, comparing BEP with BOP-VIP. Proc Am Soc Clin Oncol 1995; 14: abst 657.
9. Zuk RJ, Jenkins BJ, Martin JE, Oliver RTD, Baithun SI. Findings in lymph nodes of patients with germ cell tumours after chemotherapy and their relation to prognosis. J Clin Pathol 1989; 42: 1049-54.
10. Oliver RTD, Ong J, Ostrowski J, et al. Anglian germ cell cancer group 3 v 4 courses and 3 v 5 day EBCi/BEP pilot studies for metastatic non-seminoma (G2/3) germ cell cancer. Br J Cancer 1996; 74 (Suppl. 28): abst p016.
11. Horwich A, Oliver RTD, Fossa SD, Wilkinson P, Mead GM, Stennihg S. A randomised MRC trial comparing single agent carboplatin with the combination of etoposide and cisplatin in patients with advanced metastatic seminoma. Proc Am Soc Clin Oncol 1996; 15: abst 668.
12. Gospodarowicz MK, The Princess Margaret Hospital experience in the management of stage I and II seminoma 1981-1991. In: Jones WO (ed.) Germ Cell Tumours III. Advances in the Biosciences, Vol. 91. Oxford: Pergamin, 1994: 177-85.
13. Yao WQ, Fossa SD, Dearnaley DP, Horwich A. Combined single course carboplatin with radiotherapy in treatment of stage IIa,b seminoma - a preliminary report. Radiother & Oncol 1994; 33: 88-90.
14. Oliver RTD, Ong J. Seventeen years experience of phase I/II studies of single agent platinum compounds as alternatives to radiation for metastatic and stage I seminoma. Proc Am Soc Clin Oncol 1996; 15: 244, abst 613.
15. Oliver RTD, Edmonds PM, Ong JYH, Ostrowski MJ, Jackson AW. Pilot studies of 2 and 1 course Carboplatin as adjuvant for Stage I semimona: should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 1994; 29: 3-8.
16. Oliver RTD. Results and late effects of treatment for early-stage germ cell tumours. In: Tobias J, Thomas P (eds) Current Radiation Oncology, Vol. 2. London: Arnold, 1996: 390-416.
17. Olivarez D, Ulbright T, De-Riese W, Foster R, Reister T, Einhorn L, Sledge G. Neovascularization in clinical Stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res 1994; 54: 2800-2.
18. Osterlind A, Berthelsen JG, Abildgaard N. Risk of Bilateral Testicular Germ Cell Cancer in Denmark; 1960-1984. J Natl Cancer Inst 1991; 83: 1391-5.
19. Oliver RTD. Prognostic Classification of Metastatic Seminoma. In: Horwich A (ed.) Testicular Cancer. (2nd edn) London: Chapman & Hall, 1995: 73-84.
20. Bernadi D, Salvioni R, Vaccher E. et al. Testicular germ cell tumors and Human Immunodeficiency Virus infection: a report of 26 cases. J Clin Oncol 1995; 13: 2705-11.
21. Nouri AME, Hussain RF, Oliver RTD, Handy AM, Bartkova I, Bodmer JG. Immunological paradox in testicular tumours: the presence of a large number of activated T cells despite the complete absence of MHC antigens. Eur J Cancer 1993; 29A: 1895-9.
22. Oliver RTD. Clues from natural history and results of treatment supporting the monoclonal origin of germ cell tumours. Cancer Surveys 1990; 9: 332-68.
23. Nouri AME, Baithune S, Oliver RTD. Tetraploid arrest with over expressed non-nutated p53 in germ cell cancers: relevance to their chemosensitivity and possible application in non-germ cell cancers. Eur J Cancer (submitted).
24. Lewis CR, Fossa SD, Mead G, et al. BOP/VIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 1991; 2: 203-11.
25. Horwich A, Brada M, Nicholls J, et al. Intensive induction chemotherapy for poor risk non-seminoma. Eur J Cancer 1989; 25: 177-84.
26. Horwich A, Dearnaley DP, Norman A, Nicholls J, Hendry WF. Accelerated chemotherapy for poor-prognosis germ-cell tumors. Eur J Cancer 1994; 30a: 1607-11.
27. Bokemeyer C, Harstrick A, Metzner B. et al. Sequential high dose VIP-chemotherapy plus peripheral stem cell (PBSC) support for advanced germ cell cancer. Ann Oncol 1996; 7 (Suppl. 5): abst 2590.
28. Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high risk stage I nonseminomatous germ cell tumours of the testis: A Medical Research Council report. J Clin Incol 1996; 14: 1106-13.
29. Freedman LS, Parkinson MC, Jones WG, et al. Histopathology in the prediction of relapse of patients with stage 1 testicular teratoma treated by orchidectomy alone. On behalf of MRC Testicular Tumour Subgroup (Urological Working Party). Lancet 1987; ii: 294-8.